Patents Assigned to AVEO Pharmaceuticals, Inc.
-
Patent number: 11897948Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.Type: GrantFiled: November 2, 2018Date of Patent: February 13, 2024Assignee: AVEO Pharmaceuticals, Inc.Inventors: Jeno Gyuris, Lorena Lerner
-
Patent number: 11725047Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.Type: GrantFiled: March 19, 2020Date of Patent: August 15, 2023Assignee: AVEO Pharmaceuticals, Inc.Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 11680108Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: October 29, 2019Date of Patent: June 20, 2023Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 11504365Abstract: Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.Type: GrantFiled: April 14, 2022Date of Patent: November 22, 2022Assignee: AVEO Pharmaceuticals, Inc.Inventors: Michael P. Bailey, Michael N. Needle
-
Patent number: 11142573Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation and/or overexpression of Notch3.Type: GrantFiled: April 28, 2017Date of Patent: October 12, 2021Assignee: AVEO PHARMACEUTICALS, INC.Inventors: Heidi Okamura, William M. Winston, Jr., Laura Poling, Alisa C. Bell
-
Patent number: 10745476Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.Type: GrantFiled: January 8, 2018Date of Patent: August 18, 2020Assignee: AVEO Pharmaceuticals, Inc.Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 10597444Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.Type: GrantFiled: July 20, 2017Date of Patent: March 24, 2020Assignee: AVEO Pharmaceuticals, Inc.Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 10494441Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: March 2, 2017Date of Patent: December 3, 2019Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 9896730Abstract: The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.Type: GrantFiled: April 25, 2012Date of Patent: February 20, 2018Assignees: OSI Pharmaceuticals, LLC, AVEO PHARMACEUTICALS, INC.Inventors: Julie Kan, Stuart Thomson, Gretchen M. Argast, Matthew E. O'Connor, Murray Robinson, Bin Feng, Joerg Heyer, Maria I. Chiu, Richard Nicoletti
-
Patent number: 9879083Abstract: Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.Type: GrantFiled: December 19, 2013Date of Patent: January 30, 2018Assignee: AVEO Pharmaceuticals, Inc.Inventors: Heidi Okamura, Sandra Abbott, Alisa C. Bell, Kelly Kreuter, Ronan O'Hagan, Samantha Perino, Hamid Tissire, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 9828635Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.Type: GrantFiled: October 5, 2012Date of Patent: November 28, 2017Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris
-
Patent number: 9725505Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.Type: GrantFiled: September 24, 2015Date of Patent: August 8, 2017Assignee: AVEO Pharmaceuticals, Inc.Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria I. Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
-
Publication number: 20170137506Abstract: The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.Type: ApplicationFiled: June 19, 2015Publication date: May 18, 2017Applicant: AVEO Pharmaceuticals, Inc.Inventors: Jeno Gyuris, Lorena Lerner
-
Patent number: 9598498Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: January 4, 2016Date of Patent: March 21, 2017Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 9345788Abstract: A reconstituted human breast tumor model is disclosed. The model, which is incorporated into mice, provides actual tumors that arise spontaneously, thereby mimicking naturally occurring breast cancer. The tumors are genetically human, because they arise from human mammary tissues that develop from human mammary epithelial cells implanted into host mice. Prior to implantation, the mammary epithelial cells are genetically modified to contain a recombinant human oncogene and an SV40 early region.Type: GrantFiled: June 28, 2005Date of Patent: May 24, 2016Assignee: AVEO Pharmaceuticals, Inc.Inventors: Min Wu, Charlotte Kuperwasser, Murray Robinson
-
Patent number: 9228021Abstract: Monoclonal antibodies that bind and inhibit activation of epidermal growth factor receptor related member ErbB3/HER3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of ErbB3/HER3.Type: GrantFiled: June 17, 2013Date of Patent: January 5, 2016Assignee: AVEO Pharmaceuticals, Inc.Inventors: Sylvie Vincent, William M. Winston, Jr., Fang Wang, Solly Weiler, Kristan Meetze, Lyne Breault, Steve Bottega, Ting Chen, Michael DePrima, Christina Fleet, Steven Tyler, Jin-Kyeung Woo, Jeno Gyuris
-
Patent number: 9175076Abstract: Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.Type: GrantFiled: December 20, 2013Date of Patent: November 3, 2015Assignee: AVEO Pharmaceuticals, Inc.Inventors: Lorena Lerner, Sandra Abbott, Ailin Bai, Ting Chen, Maria Isabel Chiu, Qing Liu, Laura Poling, Nianjun Tao, Solly Weiler, Zhigang Weng, William M. Winston, Jr., Jeno Gyuris
-
Patent number: 9096664Abstract: The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors.Type: GrantFiled: October 2, 2013Date of Patent: August 4, 2015Assignees: AVEO Pharmaceuticals, Inc., Xoma Technologies, Ltd.Inventors: William M. Winston, Jr., S. Kirk Wright, May Han, Lyne Breault, Jie Lin, Bijan Etemad-Gilbertson, Christine Knuehl, Jeno Gyuris, Arnold Horwitz
-
Patent number: 8829164Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.Type: GrantFiled: November 1, 2013Date of Patent: September 9, 2014Assignee: AVEO Pharmaceuticals, Inc.Inventors: Kerry Whalen, Steve Bottega, Andrea Boudrow, Lyne Breault, Ting Chen, James Gifford, May Han, Jinwei Jiang, Lorena Lerner, Qing Liu, Kristan Meetze, Sylvie Vincent, Solly Weiler, William M. Winston, Jr., Jeno Gyuris
-
Publication number: 20140242597Abstract: A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.Type: ApplicationFiled: October 5, 2012Publication date: August 28, 2014Applicant: AVEO PHARMACEUTICALS, INC.Inventors: Sylvie Vincent, Kristan Meetze, Bin Feng, Steven Tyler, Steve Bottega, Richard Nicoletti, Donna McIntosh, Jeno Gyuris